Drug Discovery World

SEPTEMBER 26, 2022

DDW Editor Reece Armstrong explores the rise of drug repurposing and the benefits and disadvantages it brings to drug discovery and development. . Drug repurposing, the act of finding new clinical targets for both approved and unapproved drugs, has emerged as a viable alternative to traditional drug discovery approaches. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

AUGUST 3, 2023

In the first part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of medical cannabis in drug discovery. There is, however, one cannabis-derived drug product that the FDA has approved, which is Epidiolex (cannabidiol). What is the regulatory landscape of medical cannabis?

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

Practical Cheminformatics

DECEMBER 7, 2023

A recent editorial by Dean Brown in J Med Chem and follow-up posts by Keith Hornberger and Derek Lowe prompted me to think about how we train computational chemists and cheminformaticians for careers in drug discovery. It is rare for graduate students to be exposed to tasks like optimizing pharmacokinetics or off-target binding.

Computational Chemistry 90

Computational Chemistry Pharmacokinetics Pharmaceutical Companies Drugs 90

The Pharma Data

AUGUST 21, 2020

Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. After focusing on antimicrobial research for years, Leeds now heads a BD&L effort that builds relationships and collaborations with companies on the West Coast of the US and across all of Canada.

Virus 52

Virus Small Molecule Licensing Licensing 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

NOVEMBER 6, 2020

With the opinions expressed at the Advisory Committee and the data presented, the FDA will continue the review process with a decision on whether to approve the aducanumab Biologics License Application by March 7, 2021. . Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

OCTOBER 27, 2020

Impairment of investment in privately-held company (2). Unrealized gain on investment in privately-held company (3). License-related fees (5). License-related fees (5). 2020.

FDA 40

FDA Production Licensing Licensing 40